Back to Search Start Over

133MO Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966.

Authors :
Finn, R.S.
Ueno, M.
Yoo, C.
Ren, Z.
Furuse, J.
Kelley, R.K.
Chan, S.L.
Edeline, J.
Klumpen, H.J.
Yau, T.
Oh, S.C.
Ozaka, M.
Kim, J.G.
Park, J.O.
Vogel, A.
Valle, J.W.
Yu, L.
Malhotra, U.
Siegel, A.B.
Qin, S.
Source :
Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1523-S1523. 1p.
Publication Year :
2023

Subjects

Subjects :
*PEMBROLIZUMAB
*CISPLATIN
*GEMCITABINE
BILIARY tract cancer

Details

Language :
English
ISSN :
09237534
Volume :
34
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
173758152
Full Text :
https://doi.org/10.1016/j.annonc.2023.10.269
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details